Overview

A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis

Status:
Active, not recruiting
Trial end date:
2022-11-04
Target enrollment:
Participant gender:
Summary
The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients with relapsing multiple sclerosis.
Phase:
Phase 3
Details
Lead Sponsor:
Celgene
Treatments:
Ozanimod